A union in reperfusion: The concept of facilitated percutaneous coronary intervention

Journal of the American College of Cardiology

Volumn 36, Issue 5, 2000, Pages 1497-1499

  Gibson, C Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

DRUG RESEARCH; EDITORIAL; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION;

EID: 0034332696     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00926-8     Document Type: Editorial

References (20)

1. Primary angioplasty versus thrombolysis. New issues in the era of glycoprotein 2b3a inhibition and stenting
2. The relationship of the TIMI myocardial perfusion grade to mortality following thrombolytic administration
3. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction
4. Abciximab improves both epicardial flow and myocardial reperfusion in ST elevation myocardial infarction: A TIMI-14 analysis
5. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial
6. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 pilot) trial
7. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction
8. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty
9. Immediate versus delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction
10. Abciximab facilitates the rate and the extent of thrombolysis: Results of TIMI-14 trial
11. Degree of residual stenosis in the culprit artery after thrombolytic administration
12. Rescue angioplasty in the TIMI-4 Trial
13. Determinants of coronary blood flow following thrombolytic administration
14. Abciximab improves microvascular function after rescue PCI: A TIMI-14 substudy
15. Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results
16. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: In-hospital and 30-day results of the PAMI stent pilot trial
17. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
18. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relationship to angiographic outcomes in the TIMI-10B trial
19. Relationship of door-to-balloon time to mortality in patients with acute myocardial infarction treated with primary angioplasty